Novartis Scemblix^®, with Novel Mechanism of Action, Shows Superior, Long-Term Efficacy and Consistent Tolerability in 96-Week Follow-Up of Chronic Myeloid Leukemia Trial

Novartis announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.